Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008

Blood

Volumn 121, Issue 15, 2013, Pages 2996-3004

  Morton, Lindsay M ^a   Dores, Graça M ^a,b   Tucker, Margaret A ^a   Kim, Clara J ^a   Onel, Kenan ^c   Gilbert, Ethel S ^a   Fraumeni Jr , Joseph F ^a   Curtis, Rochelle E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANUS CANCER; ARTICLE; BLADDER CANCER; BONE CANCER; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; COLON CANCER; DRUG INDUCED CANCER; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FEMALE; HODGKIN DISEASE; HUMAN; LARYNX CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; STOMACH CANCER; TESTIS CANCER; UNITED STATES; UTERINE CERVIX CANCER; ACUTE DISEASE; AGE; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; MYELOID LEUKEMIA; NEOPLASM; POISSON DISTRIBUTION; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICS; TIME;

ACUTE DISEASE; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASMS; POISSON DISTRIBUTION; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; TIME FACTORS; UNITED STATES;

MLCS; MLOWN;

EID: 84876551509     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-448068     Document Type: Article

References (49)

1. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2009/; 2012.
2. Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer. 2002;33(4):331-345. (Pubitemid 34208796)
3. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35(4):418-429.
4. Czader M, Orazi A. Therapy-related myeloid neoplasms. Am J Clin Pathol. 2009;132(3):410-425.
5. Leone G, Fianchi L, Pagano L, et al. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact. 2010;184(1-2):39-45.
6. Curtis RE, Boice JD Jr, Stovall M, et al. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. J Natl Cancer Inst. 1994;86(17):1315-1324. (Pubitemid 24276793)
7. Little MP, Weiss HA, Boice JD Jr, et al. Risks of leukemia in Japanese atomic bomb survivors, in women treated for cervical cancer, and in patients treated for ankylosing spondylitis. Radiat Res. 1999;152(3):280-292. (Pubitemid 29413664)
8. Wright JD, St Clair CM, Deutsch I, et al. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer. 2010;116(10):2486-2492.
9. Curtis RE, Hankey BF, Myers MH, et al. Risk of leukemia associated with the first course of cancer treatment: an analysis of the Surveillance, Epidemiology, and End Results Program experience. J Natl Cancer Inst. 1984;72(3):531-544. (Pubitemid 14161149)
10. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008
11. Yasui Y, Liu Y, Neglia JP, et al. A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. Am J Epidemiol. 2003;158(11):1108-1113. (Pubitemid 37475095)
12. Curtis RE, Boice JDJ Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992;326(26):1745-1751.
13. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Philadelphia Bone Marrow Transplant Group. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med. 2000;342(15):1069-1076. (Pubitemid 30207689)
14. Praga C, Bergh J, Bliss J, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005;23(18):4179-4191. (Pubitemid 46211324)
15. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28(17):2914-2924.
16. Levine MN, Whelan T. Adjuvant chemotherapy for breast cancer - 30 years later. N Engl J Med. 2006;355(18):1920-1922. (Pubitemid 44664651)
17. Moser EC, Noordijk EM, van Leeuwen FE, et al. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica. 2006;91(11):1481-1488. (Pubitemid 44736114)
18. Tarella C, Passera R, Magni M, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011;29(7):814-824.
19. Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol. 2010;28(33):4935-4944.
20. Cheson BD. Time to remember to forget dose-intensification in lymphoma. J Clin Oncol. 2011;29(30):3954-3956.
21. Pouget JP, Navarro-Teulon I, Bardiès M, et al. Clinical radioimmunotherapy - the role of radiobiology. Nat Rev Clin Oncol. 2011;8(12):720-734.
22. Bauer K, Rancea M, Roloff V, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev. 2012;11:CD008079.
23. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999;340(5):351-357. (Pubitemid 29090800)
24. Vay A, Kumar S, Seward S, et al. Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis. Gynecol Oncol. 2011;123(3):456-460.
25. Kapoor P, Rajkumar SV, Dispenzieri A, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 2011;25(4):689-696.
26. Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood. 2011;118(15):4086-4092.
27. FDA Drug Safety Communication: Ongoing safety review of Revlimid (lenalidomide) and possible increased risk of developing new malignancies. Available at: www.fda.gov/Drugs/DrugSafety/ucm302939.htm. Accessed August 2, 2012.
28. Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst. 1997;89(23):1782-1788. (Pubitemid 27516232)
29. Chuang SC, Scélo G, Lee YC, et al. Risks of second primary cancer among patients with major histological types of lung cancers in both men and women. Br J Cancer. 2010;102(7):1190-1195.
30. Rajeswaran A, Trojan A, Burnand B, et al. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer. 2008;59(1):1-11.
31. Gridelli C, Maione P, Rossi A, et al. New avenues for second-line treatment of metastatic non-small-cell lung cancer. Expert Rev Anticancer Ther. 2009;9(1):115-124.
32. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin's disease. N Engl J Med. 1990;322(1):7-13. (Pubitemid 20023826)
33. Delwail V, Jais JP, Colonna P, et al. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol. 2002;118(1):189-194. (Pubitemid 34779536)
34. Pedersen-Bjergaard J, Pedersen M, Myhre J, et al. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia. 1997;11(10):1654-1660. (Pubitemid 27458603)
35. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548-4554.
36. Chang H, Liaw C-C, Chang H-K. Therapy-related acute myeloid leukemia after concurrent chemoradiotherapy for esophageal cancer: report of two cases. Tumori. 2009;95(3):371-373.
37. Samanta DR, Senapati SN, Sharma PK, et al. Acute myelogenous leukemia following treatment of invasive cervix carcinoma: a case report and a review of the literature. J Cancer Res Ther. 2009;5(4):302-304.
38. Mimura N, Tsujimura H, Ise M, et al. Therapy-related leukemia following chemoradiotherapy for esophageal cancer. Eur J Haematol. 2010;85(4):353-357.
39. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086-1092.
40. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(28):4649-4655.
41. Homesley HD. Present status and future direction of clinical trials in advanced endometrial carcinoma. J Gynecol Oncol. 2008;19(3):157-161.
42. Mazhar D, Waxman J. Early chemotherapy in prostate cancer. Nat Clin Pract Urol. 2008;5(9):486-493.
43. Bhatia S, Krailo MD, Chen Z, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood. 2007;109(1):46-51. (Pubitemid 46053041)
44. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903-2909. (Pubitemid 46630593)
45. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352(5):476-487.
46. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859-866. (Pubitemid 37025405)
47. Cronin DP, Harlan LC, Clegg LX, et al. Patterns of care in a population-based random sample of patients diagnosed with non-Hodgkin's lymphoma. Hematol Oncol. 2005;23(2):73-81. (Pubitemid 41774990)
48. Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol. 2003;21(18):3488-3494. (Pubitemid 46594082)
49. Harlan LC, Abrams J, Warren JL, et al. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol. 2002;20(7):1809-1817. (Pubitemid 34273270)